Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease

Nephrology ◽  
2016 ◽  
Vol 21 (2) ◽  
pp. 122-132 ◽  
Author(s):  
Allison Tong ◽  
David J. Tunnicliffe ◽  
Pamela Lopez-Vargas ◽  
Andrew Mallett ◽  
Chirag Patel ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Consumer Perspectives ◽  
Autosomal Dominant Polycystic Kidney

scholarly journals Erratum to: Evidence-based clinical practice guidelines for polycystic kidney disease 2014

2016 ◽  
Vol 20 (4) ◽  
pp. 510-510
Author(s):  
Shigeo Horie ◽  
Toshio Mochizuki ◽  
Satoru Muto ◽  
Kazushige Hanaoka ◽  
Yoshimitsu Fukushima ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Evidence Based ◽  
Polycystic Kidney

Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression

2018 ◽  
Vol 48 (4) ◽  
pp. 308-317 ◽  
Author(s):  
Mónica Furlano ◽  
Irene Loscos ◽  
Teresa Martí ◽  
Gemma Bullich ◽  
Nadia Ayasreh ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Rapid Progression ◽  
Kidney Volume ◽  
Polycystic Kidney ◽  
Decision Algorithm ◽  
Autosomal Dominant Polycystic Kidney ◽  
The Impact

Background: Autosomal dominant polycystic kidney disease (ADPKD) causes the development of renal cysts and leads to a decline in renal function. Limited guidance exists in clinical practice on the use of tolvaptan. A decision algorithm from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Working Groups of Inherited Kidney Disorders and European Renal Best Practice (WGIKD/ERBP) has been proposed to identify candidates for tolvaptan treatment; however, this algorithm has not been assessed in clinical practice. Methods: Eighteen-month cross-sectional, unicenter, observational study assessing 305 consecutive ADPKD patients. The ERA-EDTA WGIKD/ERBP algorithm with a stepwise approach was used to assess rapid progression (RP). Subsequently, expanded criteria based on the REPRISE trial were applied to evaluate the ­impact of extended age (≤55 years) and estimated glomerular filtration rate (eGFR; ≥25 mL/min/1.73 m2). Results: Historical eGFR decline, indicative of RP, was fulfilled in 26% of 73 patients who were candidates for RP assessment, mostly aged 31–55 years. Further tests including ultrasound and MRI measurements of kidney volume plus genetic testing enabled the evaluation of the remaining patients. Overall, 15.7% of patients met the criteria for rapid or likely RP using the algorithm, and the percentage increased to 27% when extending age and eGFR. Conclusions: The ERA-EDTA WGIKD/ERBP algorithm provides a valuable means of identifying in routine clinical practice patients who may be eligible for treatment with tolvaptan. The impact of a new threshold for age and eGFR may increase the percentage of patients to be treated.

scholarly journals Evidence-based clinical practice guidelines for polycystic kidney disease 2014

2016 ◽  
Vol 20 (4) ◽  
pp. 493-509 ◽  
Author(s):  
Shigeo Horie ◽  
Toshio Mochizuki ◽  
Satoru Muto ◽  
Kazushige Hanaoka ◽  
Yoshimitsu Fukushima ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Evidence Based ◽  
Polycystic Kidney
Sign in / Sign up

Export Citation Format

Share Document